Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is -0.72% lower on its value in year-to-date trading and has touched a low of $197.47 and a high of $306.08 in the current 52-week trading range. The VRTX stock was last observed hovering at around $237.00 in the last trading session, with the day’s loss setting it -2.36% off its average median price target of $285.00 for the next 12 months. It is also 31.59% off the consensus price target high of $343.00 offered by 28 analysts, but current levels are -6.65% lower than the price target low of $220.00 for the same period.
Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.
Currently trading at $234.64, the stock is 1.13% and 4.50% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.26 million and changing -1.00% at the moment leaves the stock -8.86% off its SMA200. VRTX registered 2.49% gain for a year compared to 6-month loss of -17.62%. The firm has a 50-day simple moving average (SMA 50) of $229.39 and a 200-day simple moving average (SMA200) of $252.93.
The stock witnessed a 4.57% gain in the last 1 month and extending the period to 3 months gives it a -13.08%, and is 2.27% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.70% over the week and 2.38% over the month.
Vertex Pharmaceuticals Incorporated (VRTX) has around 3000 employees, a market worth around $59.96B and $5.99B in sales. Current P/E ratio is 22.96 and Fwd P/E is 20.47. Profit margin for the company is 44.90%. Distance from 52-week low is 18.82% and -23.34% from its 52-week high. The company has generated returns on investments over the last 12 months (14.70%).
Vertex Pharmaceuticals Incorporated (VRTX) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Vertex Pharmaceuticals Incorporated (VRTX) is a “Buy”. 28 analysts offering their recommendations for the stock have an average rating of 1.90, where 5 rate it as a Hold and 3 think it is a “Overweight”. 20 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Vertex Pharmaceuticals Incorporated is expected to release its quarterly report on 05/05/2021 and quarterly earnings per share for the current quarter are estimated at $2.57 with sales reaching $1.58B over the same period.The EPS is expected to grow by 118.10% this year, but quarterly earnings will post 53.30% year-over-year. Quarterly sales are estimated to grow 25.50% in year-over-year returns.
Vertex Pharmaceuticals Incorporated (VRTX) Top Institutional Holders
1,397 institutions hold shares in Vertex Pharmaceuticals Incorporated (VRTX), with 234.03k shares held by insiders accounting for 0.09% while institutional investors hold 95.76% of the company’s shares. The shares outstanding are 260.39M, and float is at 259.67M with Short Float at 1.25%. Institutions hold 95.68% of the Float.
The top institutional shareholder in the company is Blackrock Inc. with over 25.18 million shares valued at $6.85 billion. The investor’s holdings represent 9.68% of the VRTX Shares outstanding. As of Sep 29, 2020, the second largest holder is Vanguard Group, Inc. (The) with 20.69 million shares valued at $5.63 billion to account for 7.96% of the shares outstanding. The other top investors are Price (T.Rowe) Associates Inc which holds 20.37 million shares representing 7.83% and valued at over $5.54 billion, while FMR, LLC holds 7.74% of the shares totaling 20.14 million with a market value of $5.48 billion.
Vertex Pharmaceuticals Incorporated (VRTX) Insider Activity
A total of 96 insider transactions have happened at Vertex Pharmaceuticals Incorporated (VRTX) in the last six months, with sales accounting for 77 and purchases happening 19 times. The most recent transaction is an insider sale by Sachdev Amit, the company’s EVP, Chief Patient Officer. SEC filings show that Sachdev Amit sold 42 shares of the company’s common stock on Nov 16 at a price of $223.53 per share for a total of $9388.0. Following the sale, the insider now owns 35103.0 shares.
Vertex Pharmaceuticals Incorporated disclosed in a document filed with the SEC on Nov 16 that Parini Michael (EVP, Chief Adm, Leg & BD Off) sold a total of 91 shares of the company’s common stock. The trade occurred on Nov 16 and was made at $223.53 per share for $20341.0. Following the transaction, the insider now directly holds 26838.0 shares of the VRTX stock.
Still, SEC filings show that on Nov 16, Arbuckle Stuart A (EVP, Chief Commercial Officer) disposed off 7 shares at an average price of $223.64 for $1565.0. The insider now directly holds 35,179 shares of Vertex Pharmaceuticals Incorporated (VRTX).
Vertex Pharmaceuticals Incorporated (VRTX): Who are the competitors?
The company’s main competitors (and peers) include Johnson & Johnson (JNJ) that is trading 9.86% up over the past 12 months. Bristol-Myers Squibb Company (BMY) is -0.40% down on the 1-year trading charts. Short interest in the company’s stock has risen 15.38% from the last report on Nov 12, 2020 to stand at a total of 2.75 million short shares sold with a short interest ratio of 1.74.